HL186

HL186 is a novel monoclonal antibody developed as an immune checkpoint inhibitor targeting T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). It is being investigated primarily for the treatment of cancer, with the goal of inhibiting tumor growth by modulating immune responses. By blocking TIM-3, HL186 aims to enhance anti-tumor immunity, potentially overcoming resistance mechanisms associated with other checkpoint inhibitors. The drug is part of HanAll Biopharma's oncology pipeline and represents a next-generation approach in immuno-oncology designed to address unmet needs in cancer therapy[5][8][1].